Abbott announces FDA approval and launch of next-generation XIENCE Xpedition Abbott announced that the XIENCE Xpedition Everolimus Eluting Coronary Stent System received FDA approval and is launching immediately in the United States, providing physicians with a next-generation technology with the largest size matrix in the U.S. market. XIENCE Xpedition features a new stent delivery system designed to optimize deliverability, particularly in challenging coronary anatomies.
News For ABT From The Last 14 Days
Check below for free stories on ABT the last two weeks.
Abbott upgraded to Buy from Neutral at Goldman Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38.
Subscribe for More Information